Overview

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Status:
Recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be a good candidate for challenging the platinum-etoposide regimen in patients with metastatic G3 NEC of GEP or unknown origin. Furthermore, in order to get insights in the putative predictive biomarkers of efficacy of these two regimens, an effort toward a precise molecular characterization of these tumors is required in order to be able to define which subgroup of G3 NEC needs to be treated by which chemotherapy regimen. The FOLFIRINEC trial is set up in order to try to answer these questions

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire Dijon
Federation Francophone de Cancerologie Digestive

Collaborator:

National Cancer Institute, France

Treatments:

Carboplatin
Cisplatin
Etoposide
Etoposide phosphate
Folfirinox